A dual-action nanomaterial uses cancer’s own chemistry to destroy tumors while leaving healthy cells unharmed.

The National Cancer Institute has quietly moved a familiar and polarizing drug into its preclinical pipeline: ivermectin, ...

Overcoming tumor resistance to chemotherapy drugs has long been a challenge for oncology clinicians and researchers. Now, a new study suggests that blocking a key protein, p300, may force damaged ...

DNA's iconic double helix does more than "just" store genetic information. Under certain conditions, it can temporarily fold ...

Engineered yeast cells can mimic real cancer cells and be used to test new cancer immunotherapies much faster, benefiting patients.

The first study on deuterium-depleted water (DDW) concluded that a higher D/H ratio inside cells can trigger cell division.

The scientists found that KLF5 had the greatest effect specifically promoting the growth and invasion of metastatic cells, ...

An international research team with strong participation from DTU has developed a new biotechnological platform that makes it possible to test and understand advanced cancer treatments much faster and ...

Daniele Canzio, PhD, of the Department of Neurology and Balyn Zaro, PhD, of the Department of Pharmaceutical Chemistry have ...

Cancer Research Institute, New York, NY, USA. The cancer cell therapy landscape continues to evolve rapidly. In 2024, the first approvals of tumour-infiltrating lymphocyte (TIL) and T cell receptor ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Imviva Biotech's CTD402 to accelerate the ...